NIH PAR · NCI · R01
PAR-25-337: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.
- NOFO number
- PAR-25-337
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Dec 31, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2028
PAR-25-337 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-337
NIH RePORTER lists 8 projects funded under PAR-25-337 in FY2022–FY2026, with $5.0M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
8
Distinct projects, FY2022–FY2026
New awards
7
Type 1 (new project) award records
NIH funding
$5.0M
Award dollars under PAR-25-337, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 8 | 7 | $5.0M |
Institutions with the most funding
- Brigham and Women's Hospital$712K · 1 project
- University of Pennsylvania$673K · 1 project
- Dartmouth-Hitchcock Clinic$634K · 1 project
- Case Western Reserve University$630K · 1 project
- UT Southwestern Medical Center$623K · 1 project
- University of Vermont & St Agric College$595K · 1 project
- Cleveland Clinic Lerner Com-Cwru$574K · 1 project
- Simplusdx, Inc.$532K · 1 project
Funding institutes
- NCI$5.0M · 8
Activity codes funded
- R018 records
Most recent new awards
- CHAMP: Cervical Cancer Prevention Using HPV Testing with a Mobile Testing Platform (opens NIH RePORTER)
Cleveland Clinic Lerner Com-Cwru · 1R01CA299083-01A1 · NCI · Notice Sep 7, 2026
$574KR01
- Spine Laser Interstitial Thermal Therapy (opens NIH RePORTER)
Dartmouth-Hitchcock Clinic · 1R01CA307001-01A1 · NCI · Notice Aug 13, 2026
$634KR01
- A High-Performance Instrument for Brain Imaging in Combination with Whole Body PET-CT for Oncology (opens NIH RePORTER)
University of Pennsylvania · 1R01CA308968-01A1 · NCI · Notice Jul 20, 2026
$673KR01
- 3D Slicer: A unified open-source platform for advanced cancer imaging research (opens NIH RePORTER)
Brigham and Women's Hospital · 1R01CA310962-01 · NCI · Notice Jun 19, 2026
$712KR01
- Development and validation of a point-of-need screening test for hepatocellular carcinoma (opens NIH RePORTER)
Simplusdx, Inc. · 1R01CA310960-01 · NCI · Notice Jun 18, 2026
$532KR01
- An Integrated Image-Enabled Computational Model for Lung Cancer Intratumoral Therapy (opens NIH RePORTER)
University of Vermont & St Agric College · 1R01CA295677-01A1 · NCI · Notice Apr 13, 2026
$595KR01
What its predecessor PAR-21-206 funded
PAR-25-337 reissues PAR-21-206. Its funding history is the best guide to who wins under this program: 15 projects and $31.3M in FY2022–FY2026.
Projects funded
15
Distinct projects, FY2022–FY2026
New awards
13
Type 1 (new project) award records
NIH funding
$31.3M
Award dollars under PAR-21-206, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 2 | 2 | $1.2M |
| FY2023 | 8 | 5 | $4.2M |
| FY2024 | 10 | 3 | $5.6M |
| FY2025 | 21 | 2 | $9.0M |
| FY2026 | 21 | 1 | $11.3M |
Institutions with the most funding
- Johns Hopkins University$8.5M · 3 projects
- University of Pennsylvania$3.2M · 1 project
- Brigham and Women's Hospital$2.7M · 2 projects
- Basic Health International, Inc.$2.6M · 1 project
- Baylor College of Medicine$2.4M · 1 project
- International Agency for Res on Cancer$2.3M · 1 project
- University of California at Davis$2.3M · 1 project
- Yale University$2.0M · 1 project
Most recent new awards
- Targeted radionuclide therapy for non-small cell lung cancer with Lu-177 EBRGD (opens NIH RePORTER)
Molecular Targeting Technologies, Inc. · 1R01CA299133-01 · NCI · Notice Aug 24, 2026
$638KR01
- Image-guided ethyl cellulose ethanol ablation to enable treatment of cervical dysplasia in low and middle-income countries (opens NIH RePORTER)
Univ of Maryland, College Park · 1R37CA302885-01 · NCI · Notice Aug 4, 2025
$627KR37
- Development and optimization of highly effective treatments in patients with head and neck cancer using in situ implantable microdevices (opens NIH RePORTER)
Brigham and Women's Hospital · 1R01CA295683-01 · NCI · Notice Dec 13, 2024
$704KR01
- POINT of CARE: PrOviding an Innovative New Triage and Treatment strategy for Cervical cAncer scReening Efficiency (opens NIH RePORTER)
Basic Health International, Inc. · 1R01CA285369-01A1 · NCI · Notice Sep 17, 2024
$481KR01
- Adapting flow cytometry methods for early detection of acute hematologic malignancies in Kenya including the improvement of sample flow processes and technical training of personnel (opens NIH RePORTER)
Indiana University Indianapolis · 1R01CA278862-01A1 · NCI · Notice Jul 2, 2024
$521KR01
- Cue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck Cancers (opens NIH RePORTER)
Yale University · 1R01CA278212-01A1 · NCI · Notice Feb 16, 2024
$692KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-337. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 499,000 direct costs) per year.
- Project period
- The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-206.
- Companion NOFOs: PAR-25-338.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PAR-25-243Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-24-311Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.